Results 191 to 200 of about 98,807 (272)

Limited benefits of neoadjuvant therapy on R0 resection rate and overall survival in patients with resectable or locally advanced PDAC in randomized controlled trials. [PDF]

Front Med (Lausanne)
Liang H, Wu YK.
europepmc   +1 more source

Addressing the distressing: Pancreatic enzyme replacement therapy mitigates abdominal symptoms and weight loss during chemotherapy for advanced pancreatic cancer: A prospective study

Nutrition in Clinical Practice, Volume 41, Issue 4, Page 1157-1165, August 2026.
Abstract Background Pancreatic enzyme insufficiency (PEI) contributes to symptom burden and malnutrition in advanced pancreatic cancer (aPC). We aimed to evaluate the impact of pancreatic enzyme replacement therapy (PERT) on symptom burden and weight during chemotherapy.
Pamela N. Klassen, Christina A. Kim, Jessica Kasnik, Michael B. Sawyer, Sunita Ghosh, Vickie Baracos, Vera C. Mazurak   +6 more
wiley   +1 more source

Durvalumab in advanced biliary tract cancer. [PDF]

Rev Assoc Med Bras (1992)
Anhesini M, Silvinato A, Floriano I, Bernardo WM.   +3 more
europepmc   +1 more source

Standardization of postoperative adverse event reporting: A critical opportunity for improvement within the National Clinical Trials Network

Cancer, Volume 132, Issue 15, 1 August 2026.
Beth Helmink, Matthew H. G. Katz, Chandrajit P. Raut, Sumithra J. Mandrekar, Kristina Laumann, Allison Booth, Laura Hoffman, Eric A. Singer, Isabelle Bedrosian, Rebecca A. Snyder   +9 more
wiley   +1 more source

Post‐Marketing Requirements for Anticancer Drugs Approved in Japan, 2001–2024: A Cross‐Sectional Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
ABSTRACT The accelerated development of innovative anticancer therapies has led to the early approval of an increasing number of drugs. However, clinical evidence available at the time of approval is often limited, necessitating additional post‐marketing studies to supplement safety and efficacy data.
Aina Tsuno, Hiroe Kitagaki, Hideki Maeda
wiley   +1 more source

Glypican-1 targeted nanoplatform for pancreatic ductal adenocarcinoma: interpreting findings. [PDF]

J Cancer Res Clin Oncol
Abroumand Gholami A, Mansurov D, Bekmirov T.   +2 more
europepmc   +1 more source

Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta‐analysis

BJU International, Volume 138, Issue 2, Page 186-195, August 2026.
Objective To evaluate the concordance between clinical complete response (cCR) and pathological complete response (pCR) in muscle‐invasive bladder cancer (MIBC) to assess the surrogacy and prognostic value of cCR for guiding bladder‐sparing strategies.
Navid Roessler, Marcin Miszczyk, Paolo Gontero, Alessandro Dematteis, Keiichiro Miyajima, Shota Inoue, Katharina Oberneder, Markus von Deimling, Victor M. Schuettfort, Malte W. Vetterlein, Bernadett Szabados, Pawel Rajwa, Pierre I. Karakiewicz, Jeremy Yuen‐Chun Teoh, Margit Fisch, Shahrokh F. Shariat   +15 more
wiley   +1 more source

Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61-FUNGEMAX trial (France). [PDF]

EClinicalMedicine
Taieb J, Pernot S, Thuillier F, Delattre A, Vo-Quang E, Petorin C, Bourgeois V, Tougeron D, Audemar F, Vitellius C, Mosser L, Desrame J, Di Fiore F, Rinaldi Y, Pellat A, Bolliet M, Watelle F, Perrier H, Dubreuil O, Lepage C, Bachet JB.   +20 more
europepmc   +1 more source

Molecular Characterization of Ovarian Yolk Sac Tumor in a Postmenopausal Woman: Implications for Pathogenesis

Journal of Obstetrics and Gynaecology Research, Volume 52, Issue 8, August 2026.
ABSTRACT Ovarian yolk sac tumor is a rare malignant germ cell tumor that typically occurs in young women. In postmenopausal women, yolk sac tumors are extremely rare and have a poor prognosis. These tumors may arise from different biological mechanisms, as germ cells are absent in postmenopausal ovaries.
Mihiro Dejima, Minoru Nagashima, Mamiko Onuki, Miki Kushima, Akihiko Sekizawa, Koji Matsumoto   +5 more
wiley   +1 more source